Rahul Gupta

Rahul Gupta

Auto-generated profile, based on publicly available information

Rahul Gupta

Department of Internal Medicine Hemet Global Medical Center Hemet California USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2021 in Clinical Cardiology
Verified
Journal Article
Open access
PDF file
SKSabina Kumar
Sabina Kumar
CAChristina Arcuri
Christina Arcuri
SCSumanta Chaudhuri
Sumanta Chaudhuri
RGRahul Gupta
Rahul Gupta
MAMahendra Aseri
Mahendra Aseri
SSShivang Shah
Shivang Shah
Background: SARS‐CoV2 has affected more than 73.8 million individuals. While SARS‐CoV2 is considered a predominantly respiratory virus, we report a trend of bradycardia among hospitalized patients, particularly in association with mortality.Methodology: The multi‐center retrospective analysis consisted of 1053 COVID‐19 positive patients from March to August 2020. A trend of bradycardia was noted in the study population. Absolute bradycardia and profound bradycardia was defined as a sustained heart rate < 60 BPM and < 50 BPM, respectively, on two separate occasions, a minimum of 4 h apart during hospitalization. Each bradycardic event was confirmed by two physicians and exclusion criteria included: less than 18 years old, end of life bradycardia, left AMA, or taking AV Nodal blockers. Data was fetched using a SQL program through the EMR and data was analyzed using SPSS 27.0. A logistic regression was done to study the effect of bradycardia, age, gender, and BMI on mortality in the study group.Results: 24.9% patients had absolute bradycardia while 13.0% had profound bradycardia. Patients with absolute bradycardia had an odds ratio of 6.59 (95% CI [2.83–15.36]) for mortality compared with individuals with a normal HR response. The logistic regression model explained 19.6% (Nagelkerke R2) of variance in the mortality, correctly classified 88.6% of cases, and was statistically significant X2 (5)=47.10, p < .001. For each year of age > 18, the odds of dying increased 1.048 times (95% CI [1.25–5.27]).Conclusion: The incidence of absolute bradycardia was found in 24.9% of the study cohort and these individuals were found to have a significant increase in mortality.

28 July 2021 in Clinical Cardiology
Verified
Journal Article
Open access
PDF file
SKSabina Kumar
Sabina Kumar
CAChristina Arcuri
Christina Arcuri
SCSumanta Chaudhuri
Sumanta Chaudhuri
RGRahul Gupta
Rahul Gupta
MAMahendra Aseri
Mahendra Aseri
SSShivang Shah
Shivang Shah
Click on the article title to read more.

20 October 2024 in IJC Heart & Vasculature
Verified
Journal Article
Open access
RGRahul Gupta
Rahul Gupta
CUChukwuemeka Umeh
Chukwuemeka Umeh
TMTamanna Mohta
Tamanna Mohta
AVAjay Vaidya
Ajay Vaidya
AWAaron Wolfson
Aaron Wolfson
BTBhoodev Tiwari
Bhoodev Tiwari
Inadequate representation of women and racial minorities in heart failure (HF) clinical trials continues to limit the generalizability of the results. This could create a disparity in treatment for future heart failure therapies and devices. The study aims to assess the representation of women and racial minorities in recent heart failure studies involving sodium-glucose cotransporter-2 (SGLT-2) inhibitors. PubMed was used to search randomized controlled trials (RCTs) looking at SGLT-2 inhibitors and heart failure, which were published from inception to August 2024. A total of 43 RCTs with 27,703 participants were identified. The studies were published between 2018 and 2024. Seven studies (41 %) were multi-country, with 45 countries represented. The overall proportion of women enrolled in the studies was 35.6 %. The proportion of women was 24.06 % in studies that recruited only patients with HFrEF, 44.33 % in those that recruited only patients with HFpEF, and 41.4 % in those that recruited both HFrEF and HFpEF. Data on race was partially reported in 25 studies (58 %). 76 % of the pharmaceutical industry-funded studies reported race data. However, only 33.3 % of the unfunded or non-industry-funded studies reported race data. In the studies that reported race data, 72.91 % were Caucasians, 15.48 % were Asians, 5.62 % were African-American and 4.1 % were mixed race or others. In the bivariate analysis, race was more likely to be reported in studies done in the US (p < 0.001), multi-country studies (p = 0.013), and studies sponsored by pharmaceutical companies. More than a third of the study participants were more likely to be women in more recently published studies than older studies (p < 0.001). Additionally, more than a third of the study participants were more likely to be women in studies done in the US (p = 0.055). The multivariate analysis showed an increased odds of having more than a third of the study participants being women in more recently published studies (OR 1.83, 95 % CI 1.06–3.17, p = 0.031) and in studies done in the US (OR 7.69, 95 % CI 1.53–38.59, p = 0.013). Our study found that women and racial minority individuals have remained underrepresented in recent heart failure studies. Although some progress has been made over the years, more work is needed to improve data reporting and address barriers to enrollment for women and racial minority individuals in clinical trials.

20 November 2018 in Clinical Case Reports
Verified
Journal Article
Open access
PDF file
YZYazan Zayed
Yazan Zayed
BSBakr Swaid
Bakr Swaid
RGRahul Gupta
Rahul Gupta
THTarek Haykal
Tarek Haykal
DODanielle Osterholzer
Danielle Osterholzer
Key Clinical Message: New onset low back pain which is recalcitrant to usual treatment should be evaluated aggressively even in the absence of fever or neurologic deficits. Corticosteroids given for back pain will accelerate occult spinal infection and may mask symptomatology leading to more severe disease.

25 February 2026 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
RGRahul Gupta
Rahul Gupta
CBChandrashekar Bohra
Chandrashekar Bohra
KVKrishna Santosh Vemuri
Krishna Santosh Vemuri
GAGaurav Arora
Gaurav Arora
AGAmit Gulati
Amit Gulati
AHAMIT HOODA
AMIT HOODA
Drug-coated balloons (DCBs) are rapidly gaining prominence, owing to the associated expanding clinical applications and therapeutic potential in interventional cardiology. Moreover, a growing body of evidence from randomized trials, observational studies, and meta-analyses supports the efficacy of DCBs across a broad spectrum of coronary lesions, positioning these devices as a viable, stent-free alternative to conventional strategies. DCBs aim to lower the risks inherent to stent implantation, such as stent thrombosis and in-stent restenosis (ISR), and to enable abbreviated dual antiplatelet therapy in high-bleeding-risk (HBR) patients. Although drug-eluting stents (DESs) remain the current standard in percutaneous coronary intervention, DCBs are emerging as a novel and promising option in diverse clinical settings beyond ISR, including de novo lesions in both small and large vessels, bifurcation disease, patients with a high risk of bleeding, and even acute coronary syndromes. This article aims to provide a comprehensive review of the evolving role, evidence base, and expanding indications of DCB-related therapy beyond ISR.

9 July 2021 in Clinical Cardiology
Verified
Journal Article
Open access
PDF file
SKSabina Kumar
Sabina Kumar
CAChristina Arcuri
Christina Arcuri
SCSumanta Chaudhuri
Sumanta Chaudhuri
RGRahul Gupta
Rahul Gupta
MAMahendra Aseri
Mahendra Aseri
SSShivang Shah
Shivang Shah
Click on the article title to read more.